Yüklüyor......
PI3K Inhibitors: Present and Future
Inhibitors of PI3Kδ hold great potential for the therapy of CLL and B cell malignancies. After initially exciting efficacy results with idelalisib, the first in class inhibitor, the emergence of unexpected and unpredictable autoimmune toxicities, worse in less heavily treated and younger patients, h...
Kaydedildi:
| Yayımlandı: | Cancer J |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7082729/ https://ncbi.nlm.nih.gov/pubmed/31764120 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/PPO.0000000000000414 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|